Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer
Natera, Inc. (NTRA)
Last natera, inc. earnings: 2/26 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.natera.com
Company Research
Source: Business Wire
First-of-its-kind study of 1K patients evaluating the impact of adjuvant treatment escalation in patients tested with Signatera™; results to be presented at ASCO GI in Jan. 2025 AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the completion of a study using Signatera from the CALGB (Alliance)/SWOG 80702 randomized, phase III clinical trial. CALGB (Alliance)/SWOG 80702 evaluated the benefit of adding celecoxib to FOLFOX in postoperative treatment of stage III colorectal cancer (CRC) in a biomarker unselected population.This pre-specified analysis includes 1,011 CRC patients with available post-surgical plasma samples and investigates Signatera’s ability to identify a subgroup of patients who may benefit from adding celecoxib to FOLFOX. Disease free survival (DFS) and overall survival (OS) are the study’s primary and secondary endpoints, respectively.Additional details on CALGB (Alliance)/SWOG 80702In
Show less
Read more
Impact Snapshot
Event Time:
NTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTRA alerts
High impacting Natera, Inc. news events
Weekly update
A roundup of the hottest topics
NTRA
News
- Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at TD Cowen from $155.00 to $175.00. They now have a "buy" rating on the stock.MarketBeat
- Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at Craig Hallum from $121.00 to $157.00. They now have a "buy" rating on the stock.MarketBeat
- Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $135.00 to $160.00. They now have an "overweight" rating on the stock.MarketBeat
- Global Preterm Birth Diagnostic Test Kit Market Set for Strong Growth, Projected to Reach USD 316.5 Million by 2034: Key Growth Drivers and Trends | Future Market Insights, Inc. [Yahoo! Finance]Yahoo! Finance
- Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $150.00 to $165.00. They now have a "buy" rating on the stock.MarketBeat
NTRA
Earnings
- 11/12/24 - Beat
NTRA
Sec Filings
- 11/13/24 - Form 4
- 11/13/24 - Form 144
- 11/12/24 - Form 4
- NTRA's page on the SEC website